David Lewis
Stock Analyst at Morgan Stanley
(2.77)
# 1,866
Out of 4,863 analysts
270
Total ratings
67.18%
Success rate
9.44%
Average return
Main Sectors:
Stocks Rated by David Lewis
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ABT Abbott Laboratories | Maintains: Equal-Weight | $117 → $127 | $134.01 | -5.23% | 24 | Apr 17, 2025 | |
| PODD Insulet | Maintains: Equal-Weight | $273 → $300 | $306.59 | -2.15% | 22 | Nov 4, 2022 | |
| BDX Becton, Dickinson and Company | Maintains: Overweight | $272 → $275 | $172.10 | +59.79% | 23 | Oct 11, 2022 | |
| DXCM DexCom | Maintains: Equal-Weight | $91 → $91 | $83.00 | +9.64% | 21 | Jun 15, 2022 | |
| OM Outset Medical | Maintains: Overweight | $750 → $720 | $20.46 | +3,419.06% | 6 | May 5, 2022 | |
| BAX Baxter International | Maintains: Overweight | $105 → $100 | $30.82 | +224.46% | 14 | Apr 29, 2022 | |
| TMDX TransMedics Group | Maintains: Equal-Weight | $22 → $15 | $141.96 | -89.43% | 7 | Feb 25, 2022 | |
| LUNG Pulmonx | Maintains: Equal-Weight | $37 → $30 | $2.98 | +908.40% | 6 | Feb 25, 2022 | |
| HOLX Hologic | Maintains: Equal-Weight | $76 → $75 | $65.18 | +15.07% | 11 | Feb 3, 2022 | |
| NVST Envista Holdings | Maintains: Equal-Weight | $42 → $45 | $18.98 | +137.09% | 7 | Jan 7, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $68 → $60 | $69.96 | -14.24% | 12 | Jan 7, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $80 → $82 | $58.86 | +39.31% | 5 | Jan 7, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $478 → $431 | $121.11 | +255.87% | 10 | Oct 29, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $140 → $154 | $87.92 | +75.16% | 17 | Aug 25, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $41 → $40 | $17.90 | +123.46% | 8 | Aug 3, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $108 → $135 | $74.82 | +80.43% | 8 | Jul 30, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $265 → $280 | $377.12 | -25.75% | 9 | Apr 28, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $260 → $285 | $519.04 | -45.09% | 13 | Apr 21, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $18 → $19 | $6.60 | +187.88% | 2 | Apr 19, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Equal-Weight | $288 → $94 | $144.81 | -35.09% | 8 | Apr 14, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $75 → $79 | $86.20 | -8.35% | 7 | Feb 25, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $170 → $180 | $92.16 | +95.31% | 14 | Feb 8, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $178 → $187 | $155.22 | +20.47% | 11 | Jan 27, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underweight | $36 → $45 | $12.24 | +267.65% | 5 | Dec 15, 2020 |
Abbott Laboratories
Apr 17, 2025
Maintains: Equal-Weight
Price Target: $117 → $127
Current: $134.01
Upside: -5.23%
Insulet
Nov 4, 2022
Maintains: Equal-Weight
Price Target: $273 → $300
Current: $306.59
Upside: -2.15%
Becton, Dickinson and Company
Oct 11, 2022
Maintains: Overweight
Price Target: $272 → $275
Current: $172.10
Upside: +59.79%
DexCom
Jun 15, 2022
Maintains: Equal-Weight
Price Target: $91 → $91
Current: $83.00
Upside: +9.64%
Outset Medical
May 5, 2022
Maintains: Overweight
Price Target: $750 → $720
Current: $20.46
Upside: +3,419.06%
Baxter International
Apr 29, 2022
Maintains: Overweight
Price Target: $105 → $100
Current: $30.82
Upside: +224.46%
TransMedics Group
Feb 25, 2022
Maintains: Equal-Weight
Price Target: $22 → $15
Current: $141.96
Upside: -89.43%
Pulmonx
Feb 25, 2022
Maintains: Equal-Weight
Price Target: $37 → $30
Current: $2.98
Upside: +908.40%
Hologic
Feb 3, 2022
Maintains: Equal-Weight
Price Target: $76 → $75
Current: $65.18
Upside: +15.07%
Envista Holdings
Jan 7, 2022
Maintains: Equal-Weight
Price Target: $42 → $45
Current: $18.98
Upside: +137.09%
Jan 7, 2022
Maintains: Equal-Weight
Price Target: $68 → $60
Current: $69.96
Upside: -14.24%
Jan 7, 2022
Maintains: Equal-Weight
Price Target: $80 → $82
Current: $58.86
Upside: +39.31%
Oct 29, 2021
Maintains: Overweight
Price Target: $478 → $431
Current: $121.11
Upside: +255.87%
Aug 25, 2021
Maintains: Overweight
Price Target: $140 → $154
Current: $87.92
Upside: +75.16%
Aug 3, 2021
Maintains: Overweight
Price Target: $41 → $40
Current: $17.90
Upside: +123.46%
Jul 30, 2021
Maintains: Overweight
Price Target: $108 → $135
Current: $74.82
Upside: +80.43%
Apr 28, 2021
Maintains: Overweight
Price Target: $265 → $280
Current: $377.12
Upside: -25.75%
Apr 21, 2021
Maintains: Equal-Weight
Price Target: $260 → $285
Current: $519.04
Upside: -45.09%
Apr 19, 2021
Maintains: Overweight
Price Target: $18 → $19
Current: $6.60
Upside: +187.88%
Apr 14, 2021
Downgrades: Equal-Weight
Price Target: $288 → $94
Current: $144.81
Upside: -35.09%
Feb 25, 2021
Maintains: Overweight
Price Target: $75 → $79
Current: $86.20
Upside: -8.35%
Feb 8, 2021
Maintains: Overweight
Price Target: $170 → $180
Current: $92.16
Upside: +95.31%
Jan 27, 2021
Maintains: Overweight
Price Target: $178 → $187
Current: $155.22
Upside: +20.47%
Dec 15, 2020
Maintains: Underweight
Price Target: $36 → $45
Current: $12.24
Upside: +267.65%